ImmuPharma Puts On Very Brave Face After Lupus Drug Flop

The UK's ImmuPharma PLC is insisting that its investigational lupus drug Lupuzor (forigerimod) still represents a “significant opportunity” despite extremely disappointing top-line results from a much-anticipated Phase III trial.

Data from the initial analysis based on 202 patients, including those who withdrew from the study, showed that Lupuzor plus standard of care (SOC), such as steroids, anti-malarials and methotrexate, was more effective than placebo plus SOC (52.5% versus 44.6%)